Simulations Plus Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
$0.86next fiscal year
Monitoring Framework
Key Performance Indicators
Software Segment Revenue Growth Quarterly900.0%Target: Reaffirm software mix between 57% and 62% of total revenue
Total Gross Margin Quarterly6,600.0%Target: Maintain or improve from historical 59% baseline
Software Renewal Rate (Trailing 12-Month) Quarterly8,700.0%Target: Stabilize and expand cross-selling opportunities
Services Backlog Quarterly24MTarget: Support steady services revenue conversion
Watch Items
- Shareholder and Regulatory Approvals for Altaris AcquisitionTrigger: Failure to secure majority shareholder vote or antitrust clearanceAction: Re-evaluate standalone valuation; monitor potential payment of the $26 million termination fee by Altaris
- Integration and Combination with Chemical Computing Group (CCG)Trigger: Delays in post-close combination planned for Q4 2026Action: Assess operational synergies and combined product roadmap across molecular design and pharmacokinetic simulation
- Software Renewal Rates and Client RetentionTrigger: Renewal rates falling below 85% among smaller biotech/pharma clientsAction: Analyze competitive pressure from alternative biosimulation platforms and adjust pricing or packaging strategies
Research as of 19 Jun 2026